M3, Inc.
Consolidated Results for the Six Months Ended Q2 FY2026 | Revenue and Profit by Major Segment and Future Growth Strategy
For H1 FY2026, revenue was 181,853 million yen, +6% year-over-year, and operating income was 36,335 million yen, +1% year-over-year. Growth contribution from international segments, expansion of solution-based orders, and monetization progress of AI-related investments are advancing. Order backlog stands at 36.4 hundred million yen, shortfall in overseas performance has narrowed, and digitalization efforts plus rollout of new functions such as AI agents continue.
Key Figures
- Revenue: 181,853 million yen (YoY +6%)
- Operating Income: 36,335 million yen (YoY +1%)
- Interim Profit: 22,623 million yen (YoY -11%)
AI要約
Overview of Results
Consolidated results for the six months ended Q2 FY2026 show revenue of 181,853 million yen, +6% year-over-year, and operating income of 36,335 million yen, achieving growth over the prior period. Meanwhile, interim profit was 22,623 million yen, a decrease of -11% year-over-year. By segment, domestic Medical Platform, Evidence Solutions, and Site Solutions performed steadily. The international segment showed approximately +11% growth.
Outlook and Challenges
Order backlog is 36.4 hundred million yen, with expansion of solution-based orders compared with the prior year. We will promote the launch of new products including AI-enabled offerings and strengthen the sales organization. Digital transformation in clinical settings remains robust. We will continue to execute a medium-term growth strategy that expands international growth drivers while considering currency impact.
Revenue Trend
Operating Income Trend
Margin Analysis
M3, Inc.
Company overview · Stock price · Financial data · All IR
